Fisher Asset Management LLC Sells 11,917 Shares of Prestige Consumer Healthcare Inc. $PBH

Fisher Asset Management LLC reduced its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 293,709 shares of the company’s stock after selling 11,917 shares during the period. Fisher Asset Management LLC owned about 0.61% of Prestige Consumer Healthcare worth $18,327,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in PBH. Allspring Global Investments Holdings LLC grew its position in shares of Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after buying an additional 70,376 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 0.7% in the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock worth $112,843,000 after acquiring an additional 9,455 shares during the period. Westwood Holdings Group Inc. lifted its stake in shares of Prestige Consumer Healthcare by 2.4% in the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock worth $70,420,000 after acquiring an additional 20,626 shares during the period. Bank of America Corp DE boosted its holdings in Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after acquiring an additional 115,459 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Prestige Consumer Healthcare by 12.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 553,407 shares of the company’s stock valued at $44,190,000 after purchasing an additional 63,168 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. The trade was a 2.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.40% of the stock is owned by insiders.

Analysts Set New Price Targets

PBH has been the topic of a number of research analyst reports. Jefferies Financial Group cut their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Canaccord Genuity Group dropped their price objective on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Trading Up 0.2%

NYSE PBH opened at $69.13 on Thursday. The firm has a market capitalization of $3.27 billion, a P/E ratio of 18.29, a PEG ratio of 2.17 and a beta of 0.41. The business has a fifty day simple moving average of $65.65 and a 200 day simple moving average of $63.55. Prestige Consumer Healthcare Inc. has a 12 month low of $57.25 and a 12 month high of $90.04. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business’s revenue was down 2.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).